Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples

Background/Aim: Azacitidine (AZA) is a hypomethylating agent used in myeloid neoplasms, however, approximately half of patients show treatment failure or relapse. This in vitro study investigated the effect of the combination of AZA with the natural compound curcumin (CUR) in increasing its efficacy...

ver descrição completa

Detalhes bibliográficos
Autores: Martin, I, Navarro, B, Solano, C, Calabuig, M, Hernandez-Boluda, JC, Amat, P, Remigia, MJ, Garcia, F, Villamon, E, Tormo, M
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Recursos:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p3874
Acesso em linha:https://incliva.portalinvestigacion.com/publicaciones/3874
Access Level:acceso abierto
Palavra-chave:Myelodysplastic syndromes
acute myeloid leukemia
azacitidine
curcumin
synergistic activity
id ES_08bc791f9a96cf33a33cae03363d65b2
oai_identifier_str oai:incliva.fundanetsuite.com:p3874
network_acronym_str ES
network_name_str España
repository_id_str
spelling Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient SamplesMartin, INavarro, BSolano, CCalabuig, MHernandez-Boluda, JCAmat, PRemigia, MJGarcia, FVillamon, ETormo, MMyelodysplastic syndromesacute myeloid leukemiaazacitidinecurcuminsynergistic activityBackground/Aim: Azacitidine (AZA) is a hypomethylating agent used in myeloid neoplasms, however, approximately half of patients show treatment failure or relapse. This in vitro study investigated the effect of the combination of AZA with the natural compound curcumin (CUR) in increasing its efficacy. Materials and Methods: We analyzed the effects of AZA plus CUR on proliferation, apoptosis, cell cycle and differentiation in myeloid leukemic cell lines (U-937, HL-60, K-562, and OCI-AML3) and bone marrow samples of patients. Results: The results showed a synergy between AZA and CUR in all leukemic lines and in most leukemic samples, with a decrease in proliferation and an increase in apoptosis compared to the activity of each drug separately. In addition, AZA plus CUR showed low cytotoxicity in healthy samples. Conclusion: A remarkable antioncogenic effect of the combination of AZA plus CUR was shown, providing a basis for future studies analyzing the clinical efficacy of these drugs.INT INST ANTICANCER RESEARCH2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/3874ANTICANCER RESEARCHISSN: 02507005ISSNe: 17917530reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p38742026-06-07T16:35:31Z
dc.title.none.fl_str_mv Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples
title Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples
spellingShingle Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples
Martin, I
Myelodysplastic syndromes
acute myeloid leukemia
azacitidine
curcumin
synergistic activity
title_short Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples
title_full Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples
title_fullStr Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples
title_full_unstemmed Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples
title_sort Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples
dc.creator.none.fl_str_mv Martin, I
Navarro, B
Solano, C
Calabuig, M
Hernandez-Boluda, JC
Amat, P
Remigia, MJ
Garcia, F
Villamon, E
Tormo, M
author Martin, I
author_facet Martin, I
Navarro, B
Solano, C
Calabuig, M
Hernandez-Boluda, JC
Amat, P
Remigia, MJ
Garcia, F
Villamon, E
Tormo, M
author_role author
author2 Navarro, B
Solano, C
Calabuig, M
Hernandez-Boluda, JC
Amat, P
Remigia, MJ
Garcia, F
Villamon, E
Tormo, M
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Myelodysplastic syndromes
acute myeloid leukemia
azacitidine
curcumin
synergistic activity
topic Myelodysplastic syndromes
acute myeloid leukemia
azacitidine
curcumin
synergistic activity
description Background/Aim: Azacitidine (AZA) is a hypomethylating agent used in myeloid neoplasms, however, approximately half of patients show treatment failure or relapse. This in vitro study investigated the effect of the combination of AZA with the natural compound curcumin (CUR) in increasing its efficacy. Materials and Methods: We analyzed the effects of AZA plus CUR on proliferation, apoptosis, cell cycle and differentiation in myeloid leukemic cell lines (U-937, HL-60, K-562, and OCI-AML3) and bone marrow samples of patients. Results: The results showed a synergy between AZA and CUR in all leukemic lines and in most leukemic samples, with a decrease in proliferation and an increase in apoptosis compared to the activity of each drug separately. In addition, AZA plus CUR showed low cytotoxicity in healthy samples. Conclusion: A remarkable antioncogenic effect of the combination of AZA plus CUR was shown, providing a basis for future studies analyzing the clinical efficacy of these drugs.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/3874
url https://incliva.portalinvestigacion.com/publicaciones/3874
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv INT INST ANTICANCER RESEARCH
publisher.none.fl_str_mv INT INST ANTICANCER RESEARCH
dc.source.none.fl_str_mv ANTICANCER RESEARCH
ISSN: 02507005
ISSNe: 17917530
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403061618737152
score 15,811543

Registos relacionados